CRISPR Therapeutics (CRSP) Stock Price
CRISPR Therapeutics Price
Over the last 10 years CRISPR Therapeutics grew revenue by 30.4% annually, reaching 3.51 M USD. For CRISPR Therapeutics, the net margin of -16,569.8% is down versus 41.4% a few years ago. The consensus 12-month price target for CRISPR Therapeutics is 68.00 USD, about 28.4% above where the stock trades today. Of 28 analysts, 17 rate the stock a buy — an overall Buy consensus.
CRISPR Therapeutics stock price
CRISPR Therapeutics business model & stock analysis
Frequently asked questions about CRISPR Therapeutics
The business model of CRISPR Therapeutics AG is focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. The company aims to address a wide range of severe diseases by leveraging the potential of CRISPR technology to correct genetic defects. CRISPR Therapeutics AG collaborates with various partners to advance its pipeline of therapeutic candidates, spanning areas like hematology, oncology, ophthalmology, and regenerative medicine. Their goal is to bring novel and curative treatments to patients with unmet medical needs. CRISPR Therapeutics AG prioritizes innovation, strategic alliances, and continuous research to drive the advancement of gene-based therapies.
CRISPR Therapeutics AG is primarily active in the biotechnology industry.
The main competitors of CRISPR Therapeutics AG in the market are Editas Medicine, Inc., Intellia Therapeutics, Inc., and Sangamo Therapeutics, Inc.
CRISPR Therapeutics AG is a biopharmaceutical company headquartered in Switzerland. Founded in 2013, the company focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG aims to provide treatments for a wide range of diseases with unmet medical needs. Since its inception, CRISPR Therapeutics AG has made significant advancements in the field of gene editing. The company has forged numerous collaborations with leading pharmaceutical companies to accelerate the development and commercialization of potential therapies. With a robust pipeline and a team of dedicated scientists, CRISPR Therapeutics AG continues to drive innovation in the realm of precision medicine. As a leader in gene-editing technology, CRISPR Therapeutics AG remains committed to improving patients' lives through its groundbreaking research and development efforts.
CRISPR Therapeutics AG has reached several significant milestones in its journey. The company successfully initiated clinical trials for the treatment of beta-thalassemia and sickle cell disease using CRISPR-Cas9 gene editing technology. This groundbreaking approach holds great promise in revolutionizing the field of genetic medicine. Additionally, CRISPR Therapeutics AG entered into strategic collaborations with various pharmaceutical companies to develop novel therapeutics for a wide range of diseases. Moreover, the company obtained Fast Track Designation from the U.S. FDA for its CTX001 therapy, further validating its innovative approach and potential impact on patients' lives. CRISPR Therapeutics AG continues to make remarkable progress in advancing gene editing therapies for various genetic disorders.
CRISPR Therapeutics AG is primarily present in various countries and regions around the world. The company operates from its headquarters in Basel, Switzerland, providing its groundbreaking gene-editing technology globally. CRISPR Therapeutics AG has a strong presence in the United States, with research and development facilities located in Cambridge, Massachusetts. Additionally, the company has expanded its reach to other regions, including Europe and Asia. With its focus on developing transformative therapies using CRISPR-Cas9 gene-editing technology, CRISPR Therapeutics AG continues to collaborate with partners across the globe to bring innovative treatments to patients in need.
CRISPR Therapeutics AG is a leading biotechnology company known for its revolutionary gene-editing technology. The company's values lie in the belief that genetic diseases can be treated and cured using CRISPR-Cas9, a precise and efficient gene-editing tool. With a commitment to improving patients' lives, CRISPR Therapeutics AG aims to develop transformative therapies for multiple genetic disorders. Their corporate philosophy centers around innovation, dedication to scientific advancements, and collaboration with partners to ensure the rapid translation of their technology into potential treatments. Through their cutting-edge research and development, CRISPR Therapeutics AG strives to make significant contributions to the field of gene editing and ultimately bring hope to patients worldwide.
Analysts currently set an average price target of 67.83 USD for the CRISPR Therapeutics stock (median: 68.00 USD), implying +28.1 % versus the latest price. The consensus is based on 28 analyst ratings.
28 analysts currently rate the CRISPR Therapeutics stock: 17 recommend buying, 11 holding and 0 selling. For 2026, analysts expect CRISPR Therapeutics to generate revenue of 36.68 M USD and earnings per share of -4.64 USD.
Converted at the current exchange rate, the CRISPR Therapeutics share trades at 47.26 EUR (52.96 USD).
The CRISPR Therapeutics share (CRSP) is listed on 7 stock exchanges, including: NASDAQ (CRSP), London (0VRQ.L), SIX (Zürich) (1CG.SW), Frankfurt (1CG.F), München (1CG.MU), Düsseldorf (1CG.DU).
CRISPR Therapeutics AG is a biopharmaceutical company focused on the discovery and development of therapies for genetic diseases. The company uses the innovative CRISPR/Cas9 technology to make specific changes in the human genome and treat hereditary diseases. Its business model is based on researching and applying this technology to develop therapeutics for genetic diseases. CRISPR Therapeutics has a wide pipeline of products at various stages of development, from preclinical to clinical phase III. The company has an exclusive license for the therapeutic use of CRISPR/Cas9 technology from the University of California, Berkeley and the Massachusetts Institute of Technology (MIT). It has also formed a strategic alliance with Vertex Pharmaceuticals to develop new therapies for lysosomal storage diseases. One of the key products being developed by CRISPR Therapeutics is CTX001, a gene therapy for the treatment of beta-thalassemia and sickle cell disease. This therapy uses CRISPR/Cas9 to modify the patient's blood stem cells to increase the production of fetal hemoglobin and replace the defective hemoglobin. CTX001 is currently in clinical phase III development and is being jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing therapies for other genetic diseases such as hemophilia A, Duchenne muscular dystrophy, and cystic fibrosis. This is achieved by targeting disease-causing genes and using CRISPR/Cas9 to regulate gene expression. The company's business model also includes licensing its technology to other companies for the development of therapies for other diseases. It has partnered with Bayer to develop therapies for the treatment of blood and liver diseases. Overall, CRISPR Therapeutics has an innovative business model based on the use of CRISPR/Cas9 technology to make specific changes in the human genome and treat or cure genetic diseases. Through the development of CTX001 and other therapies, the company has significant potential to improve the lives of patients with genetic diseases.
The expected revenue of CRISPR Therapeutics is 36.68 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of CRISPR Therapeutics is -416.98 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of CRISPR Therapeutics is currently -11.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CRISPR Therapeutics stock.
The price-to-sales ratio (P/S) of CRISPR Therapeutics is currently 129.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CRISPR Therapeutics stock.
The Eulerpool Quality Score for CRISPR Therapeutics is 3/10.
The ISIN of CRISPR Therapeutics is CH0334081137. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of CRISPR Therapeutics is A2AT0Z. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of CRISPR Therapeutics is CRSP. The ticker symbol is used to trade CRISPR Therapeutics shares on the stock exchange.
CRISPR Therapeutics stock
CRISPR Therapeutics Peer Group
CRISPR Therapeutics Ticker
CRISPR Therapeutics FIGI
All fundamentals and in-depth analysis of CRISPR Therapeutics
Our stock analysis for CRISPR Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.